TORONTO and HAIFA, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce significant ...
TORONTO and HAIFA, Israel, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a ...
Lonza to support cGMP manufacturing of RION’s Purified Exosome Product™ (PEP™), a platelet-derived exosome-based drug candidate for chronic wound care and tissue regeneration Collaboration leverages ...
TORONTO and HAIFA, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a ...
TORONTO and HAIFA, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is ...
SINGAPORE, Jan. 5, 2026 /PRNewswire/ -- Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical's ...
PranaX Corporation, a pioneer in exosome-based regenerative wellness, proudly announces the appointment of Phillip Maderia as its new Chief Executive Officer. With over three decades of leadership in ...
RION, a commercial and clinical-stage regenerative medicine company pioneering platelet-derived exosomes for both human and animal health applications, has announced a collaboration with Lonza, one of ...